CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

Slides:

Advertisements

Similar presentations

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.

Advertisements

Identification and functional characterisation of molecular risk factors in acute leukemias Renate Kirschner 1, Michaela Heide 1, Peter Rhein 1, Leonid.

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.

MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

MiRNA-130a regulates C/EBP-ε expression during granulopoiesis by Maria T. Larsen, Mattias Häger, Andreas Glenthøj, Fazila Asmar, Stine N. Clemmensen, Helena.

Figure 2 Percentage of CD19+/CD34+ cells with decreased CD81 median fluorescence intensity (MFI;

Early T-Cell Precursor ALL in 5 Year Old Female

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study by Martin Schrappe, Maria.

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification by Estella.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.

Next-generation leukemia immunotherapy

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Gupta V, Tallman MS, Weisdorf DJ

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial.

Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Tax fingerprint in adult T-cell leukemia

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

Rapid Identification Of Compound Mutations In Patients With Ph-Positive Leukemias By Long-Range Next Generation Sequencing by Sandra Preuner, Renate Kastner,

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,

Short-pulse B–non-Hodgkin lymphoma–type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster.

How I treat extramedullary acute myeloid leukemia

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Suppression, surprise: galectin-10 and Treg cells

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia by Jose Roman-Gomez, Antonio.

Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia:

Has MRD monitoring superseded other prognostic factors in adult ALL?

Global approach to the diagnosis of leukemia using gene expression profiling by Torsten Haferlach, Alexander Kohlmann, Susanne Schnittger, Martin Dugas,

A Strong Expression of CD44-6v Correlates With Shorter Survival of Patients With Acute Myeloid Leukemia by S. Legras, U. Günthert, R. Stauder, F. Curt,

Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies by Maria C. Petti,

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Chronic Myeloid Leukemia

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

by John Anastasi, Rizwan Moinuddin, and Christopher Daugherty

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Overall survival by SCT versus observation in first complete remission

Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.

BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia by Karen A. Dun, Rob Vanhaeften, Tracey J.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Minimal Residual Disease and Hematologic Malignancies

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia by Rosemary E. Gale,

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia by Ondrej Hrusak, Valerie de Haas, Jitka Stancikova,

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Monika Brüggemann, and Michaela Kotrova

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

How I treat T-cell acute lymphoblastic leukemia in adults

Presentation transcript:

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner, Giuseppe Basso, Giuseppe Gaipa, Michael N. Dworzak, Renate Kirschner-Schwabe, Christian Hagemeier, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Leonid Karawajew, and Richard Ratei Blood Volume 115(18): May 6, 2010 ©2010 by American Society of Hematology

Correlation of CD11b mRNA at diagnosis with percentage of blasts at day 8. Peter Rhein et al. Blood 2010;115: ©2010 by American Society of Hematology

ROC curve analysis of discrimination of FCM-MRD remission status (FCM positive vs negative) and BFM risk stratification (high vs standard) according to CD11b expression levels at diagnosis. Peter Rhein et al. Blood 2010;115: ©2010 by American Society of Hematology

CD11b protein expression is consistently increased in MRD cells. Peter Rhein et al. Blood 2010;115: ©2010 by American Society of Hematology

CD11b expression in ALL blasts under therapy: modulation vs selection. Peter Rhein et al. Blood 2010;115: ©2010 by American Society of Hematology

CD11b positivity improves discrimination between ALL and normal mature and precursor B cells. Peter Rhein et al. Blood 2010;115: ©2010 by American Society of Hematology